A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

To join this study, you would need to be between 50 and 90 years old and have been diagnosed with early-stage Alzheimer's disease, showing mild memory or thinking problems. Doctors would need to confirm changes in your brain linked to Alzheimer's, often through special scans or tests.

It's very important that you're willing and able to attend all study appointments and assessments. You would also need a 'study partner' – someone who knows you well and can come with you to appointments and help with information when needed. Your memory and thinking abilities would be checked to ensure they fall within the range the study is looking for.

There are also some health conditions that would prevent you from taking part, such as other conditions that affect your thinking, certain types of brain injury or stroke, or other serious uncontrolled medical problems. The research team will carefully check your overall health and medical history to make sure the study is safe for you.

If you decide to participate, you would be asked to attend regular appointments where you'd have various tests. These include thinking and memory tests, blood tests, and potentially brain scans (like an MRI or PET scan) or a spinal fluid test (CSF). You would receive either the study medication, Trontinemab, or a placebo, which looks identical but contains no active drug. Neither you nor the study team would know which one you are receiving – this is called a 'blinded' study and helps ensure fair results. Your study partner would be an important part of your journey, helping you attend appointments and providing information. The exact number of visits, duration of treatment, and overall length of the study would be fully explained by the research team.